Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vol=420,000. Aver vol=9mill. Yep!
Nice bounce coming in next half hour.
Ty! Most are wise to otc nonsense.
Nice post! I love that commercial, almost brings a tear to your eye.
I agree about otc. Very dangerous nowadays.
I daytrade for a nice income. I only hold stocks I've deep researched, like C4. I highly recommended Apple and Tesla several years ago to family and close friends. Those that listened did very well. I hope C4 does very nicely. It has a good chance imo. Time will tell. My early track record 10 years ago was very bad. Penny stocks...who knew? Sheesh! I refuse to recommend ANYTHING on otc markets EVER again subs. I do not care about early money lost. It's the others affected I feel bad for. For that reason I post very bluntly honest. I have alot of fun nowadays with ihubub because I know I am posting with deep research, integrity and sometimes just for humor. When I see red flags on investing in C4, believe me I will post them to protect others in a stock I have posted on. Integrity matters!!! Like the relationship between a dog and a horse protecting each other. Still my favorite all time commercial!
Shorts are evil. Now we long have more evil than you can imagine! Watch your asses!
I like what I've deep researched. No worries.
LMFAO! That is hilarious!
We'll smack shorts like a paddle ball. The idiots won't know what hit em until a margin call sends them to tom sellick to sign a reverse mortgage to cover, lol.
Shorts are smacking us!
I like 96% inst owned.https://finviz.com/quote.ashx?t=CCCC&p=d
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
"Shares of C4 Therapeutics (CCCC - Free Report) , or C4T, were up 5.8% on Jan 10 after management announced strategic plans to prioritize its drug development efforts in 2024.CCCC seeks to prioritize the advancement of two of its pipeline candidates, CFT7455 and CFT1946, both of which are in early-stage development. While CFT7455 is being developed in a phase I/II study for multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) indications, CFT1946 is being evaluated in a separate phase I/II study for treating BRAF V600 mutant solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer and melanoma.
The company also intends to advance its partnered programs. It intends to support its partner, China-based Betta Pharmaceuticals, in initiating clinical development on CFT8919 in EGFR L858R mutated NSCLC patients. C4T also plans on expanding its collaborations with Merck (MRK - Free Report) , Biogen and Roche.To achieve these objectives, C4 Therapeutics will reduce its existing workforce by 30%. It reported about $330 million in unaudited cash, cash equivalents and marketable securities as of Jan 5, compared with $246.4 million balance as of Sep 30, 2023.Earlier this month, C4T closed a $25-million equity investment from Betta Pharmaceuticals. It also signed a collaboration deal with Merck last month to develop novel oncology drugs, for which the company also received a $10 million upfront payment. During fourth-quarter 2023, C4 also sold shares to the public as part of an at-the-market (ATM) offering, raising $72 million in net proceeds.C4T expects the additional capital and cost-saving efforts to extend its cash runway into 2027.Alongside the prioritization efforts, management also announced set milestones for the year. These include updated data from the ongoing phase I dose escalation studies on CFT7455 in MM and NHL indications before the year's end. It also expects a data readout in the second half of the year from the early-stage dose escalation study on CFT1946 in BRAF V600 mutated cancers.
In the past year, shares of C4T have lost 9.3% compared with the industry’s 10.9% decline.Zacks Investment Research
Image Source: Zacks Investment ResearchDecember 2023 was an important month for C4T. During this month, the company signed a collaboration deal with Merck to discover and develop degrader-antibody conjugates (DACs), with an initial focus on one oncology target. CCCC is also eligible to receive milestone payments from Merck of around $600 million and tiered royalties on net sales if a product is commercialized upon potential approval.In the same month, C4T also reported encouraging data from the phase I/II study on CFT4755. Data from the study showed that treatment with CFT4755 led to anti-myeloma activity in patients who had undergone numerous lines of prior therapy for multiple myeloma, including BCMA therapies.C4T’s top line currently comprises collaboration revenues. Hence, in the absence of a marketed product, the successful development of its pipeline candidates remains the key focus for the company. However, any regulatory or developmental setback for its candidates is likely to hurt the stock in the days ahead."
(Updated)"C4T expects the additional capital and cost-saving efforts to extend its cash runway into 2027."
Great article subs! It's the first news article after searching cccc.
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn
Agree. This month :)
CCCC is 18% short. They keep covering and then they short again late in the day. Made it to $8.40 yesterday morning
That might be pretty soon;)
Zorro buddy. I'm gonna start selling @ $10.00
Should keep moving up.
Hey subs! What's your take on this?
On January 11, 2024, C4 Therapeutics, Inc. (the “Company”) posted an investor presentation to its website at https://ir.c4therapeutics.com/events-presentations. A copy of the investor presentation is furnished herewith as Exhibit 99.1.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information
https://www.otcmarkets.com/filing/html?id=17178462&guid=3jJ-kaZlBd-Rwrh
Were back over $8.00 :)
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials
Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%
Unaudited Cash, Cash Equivalents and Marketable Securities Totaling Approximately $330 million as of January 5, 2024, Combined with Cost Savings from Restructured Operations, Results in Cash Runway into 2027
Company to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies for patients. These priorities capitalize upon recent clinical data and key decisions, resulting in a sharpened focus on executing high-potential programs to ensure achievement of near-term milestones that position C4T for future success.
Key 2024 priorities include advancing the CFT7455 and CFT1946 clinical programs to value-inflection milestones, supporting CFT8919 Phase 1 development in China by partner Betta Pharmaceuticals, delivering on three discovery collaborations and progressing a streamlined internal discovery effort. As a result of this prioritized portfolio, C4T is restructuring its operations and reducing its workforce by approximately 30%.
C4T has strengthened its balance sheet to ensure sufficient runway to execute through and beyond critical value-inflecting clinical and discovery milestones. C4T has recently received additional capital of approximately $107 million comprised of the previously announced $25 million equity investment from a subsidiary of Betta Pharmaceuticals, the $10 million upfront payment from collaborator Merck for the Degrader-Antibody Conjugate (DAC) collaboration and approximately $72 million in net proceeds generated by leveraging the company’s at-the-market (or ATM) facility. During the fourth quarter of 2023, C4T sold approximately 13.7 million shares under the ATM, at an average price of $5.42 per share, resulting in $72 million of new equity capital, net of commissions and fees.
“Building on recent momentum, we are well positioned to make meaningful advances across our portfolio in 2024. Data from the CFT7455 Phase 1 trial highlighted that the schedule adjustment is yielding expected results, including IMWG responses, and we remain focused on advancing the program to unlock its potential. In addition, we are encouraged by the early pharmacokinetic and pharmacodynamic data from the CFT1946 Phase 1 dose escalation, which confirms oral bioavailability and dose proportional exposure increases, which are associated with deep BRAF degradation,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Our sharpened focus on progressing CFT7455 and CFT1946 to critical clinical milestones, along with advancing targeted protein degradation research through our discovery collaborations with Roche, Biogen and Merck and our internal research efforts, will help C4T deliver breakthrough therapies for patients with cancer and other diseases. Our strengthened balance sheet, coupled with cost savings from our restructuring, provide sufficient runway to execute through and beyond critical milestones across the portfolio.”
Mr. Hirsch continued, “While we believe we are making mission-driven decisions to prioritize our portfolio, restructuring our company and impacting talented colleagues was not a decision we made lightly. We are grateful for their contributions to C4T and are treating our departing colleagues with compassion and support.”
2024 ANTICIPATED MILESTONES
The company announced the following key milestones for 2024:
CFT7455
Present updated data from the ongoing Phase 1 dose escalation trial in relapsed/refractory multiple myeloma (R/R MM) in 2H 2024
Present data from the ongoing Phase 1 dose escalation trial in relapsed/refractory non-Hodgkin’s lymphomas (R/R NHL) in 2H 2024
Complete Phase 1 dose exploration in R/R MM and NHL by year-end 2024
CFT1946
Present preclinical data demonstrating differentiated activity in preclinical models of BRAF V600X melanoma, colorectal cancer, non-small cell lung cancer and brain metastasis in 1H 2024
Present data from the ongoing Phase 1 dose escalation trial in melanoma, colorectal cancer, non-small cell lung cancer and other cancers with BRAF V600X mutations in 2H 2024
CFT8919
Support study start-up activities related to the Phase 1 dose escalation trial in EGFR L858R mutated non-small cell lung cancer by partner Betta Pharmaceuticals
RECENT ACHIEVEMENTS
CFT7455
In December 2023, presented positive clinical data from the ongoing CFT7455 Phase 1/2 trial in R/R MM. The data demonstrated anti-myeloma activity, including International Myeloma Working Group (IMWG) responses in patients who have undergone numerous lines of prior therapy for multiple myeloma, including BCMA therapies.
CFT1946
Pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial escalation cohorts of the ongoing CFT1946 Phase 1/2 trial in BRAF V600X mutant solid tumors demonstrate dose proportional exposure and oral bioavailability, which are associated with deep BRAF degradation.
Partnerships
Betta Pharmaceuticals
In January 2024, the previously announced $25 million stock purchase by a subsidiary of partner Betta Pharmaceuticals was completed.
In December 2023, partner Betta Pharmaceuticals received approval from the Chinese National Medical Products Administration for the Investigational New Drug application for CFT8919.
Merck
In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop DACs. Under the terms of the agreement, C4T and Merck will collaborate to develop DACs directed to an initial undisclosed oncology target exclusive to the collaboration; in January 2024, C4T received the $10 million upfront payment for this initial target. C4T is eligible to receive milestone payments totaling approximately $600 million, as well as tiered royalties on future sales, for DACs directed to this initial target.
FINANCIAL GUIDANCE
Unaudited cash, cash equivalents and marketable securities as of January 5, 2024 were approximately $330 million. The company expects that its cash, cash equivalents and marketable securities as of January 5, 2024, together with anticipated cost savings from the restructuring, will enable the company to fund its operating plan into 2027.
J.P. MORGAN PRESENTATION
C4T will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 am PST (12:00 pm EST). A live webcast will be available under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About CFT7455
CFT7455 is an orally bioavailable MonoDAC™ degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). CFT7455 is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show CFT7455 is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E-driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer and melanoma. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
About CFT8919
CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, in preclinical studies, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M and L858R-T790M-C797S. In 2023, C4T and Betta Pharmaceuticals entered into an exclusive licensing and collaboration agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results
B RY were back in the $7.00's like a month ago! Happy happy joy joy!
Agree subs! C4 is sanity. Outside, not so much. I watched an old episode of "Wanted: Dead or Alive" with Steve McQueen recently. An old cowboy asked him..."you don't like having friends do you?". Steve replied..."sure I do. Just not the ones I have to associate with". I like his attitude. I think I'll binge watch it later. I appreciate brutal honesty.
Someone screwed me for 8k last month. Where I come from In New Jersey, we keep silent for a while and then without notice, we send out collectors that you don't wanna know. People mask themselves as being honest and then BOOM they stab you in the back. I have a story back in 2005 that will blow your mind. The worst evil exists in the stock market along with other places on this Earth
I was on a conference call this morning with a group of total Wall Mart ass wipes that wasted 45 minutes of my valuable time. I was pissed off for 15 minutes then went outside and had a cigarette and came back totally calm. The newbie, well maybe he didn't read my response so I'm not gonna rag him. We are dealing with people from all around this evil World and as you are well aware most are slime baskets with the mentality of a weasle. You and I along with a few other sweet people on Ihub have to look out for ourselves. This is our bread and butter.
Yeah, all is well bro, I'm adding another line of work in Feb. In Vegas. :)
Hey buddy! Happy New Year! CCCC looks fantastic even with the short sellers and the new offering. :)
You're very kind subs. Newbie should thank you.
NEWS
CCC Intelligent Solutions Announces Pricing of Upsized Secondary Offering of 22 Million Shares of Common Stock
CHICAGO--(BUSINESS WIRE)-- CCC Intelligent Solutions Holdings Inc. (the “Company”) (NASDAQ: CCCS) today announced the pricing of the previously announced secondary offering of shares of the Company’s common stock (the “Offering”) by affiliates of Advent International, L.P. (the “Selling Stockholders”). The Offering consists of 22 million shares of the Company’s common stock, upsized from the previously announced 20 million shares. The shares will be offered from time to time for sale through negotiated transactions or otherwise at market prices prevailing at the time of sale. The Offering is expected to close on or about January 8, 2024, subject to the satisfaction of customary closing conditions. The Offering consists entirely of shares of the Company’s common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders.
J.P. Morgan, Barclays and Citigroup are acting as joint book running managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-267793), which has been filed with the Securities and Exchange Commission (“SEC”) and became effective on October 14, 2022. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus. You may get these documents for free, including the prospectus supplement, once available, by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement, once available, and the accompanying base prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, by mail at 1155 Long Island Avenue, Edgewood, New York 11717, by telephone: (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at barclaysprospectus@broadridge.com or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why = https://finance.yahoo.com/news/c4-therapeutics-cccc-gains-310-161000432.html
I'm new to CCCC, .... some experienced follower needs to give me reasons to stay with CCCC
Looking very strong today. Maybe shorts are covering?
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 330.9% in December.C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 8,100,000 shares, a growth of 330.9% from the November 30th total of 1,880,000 shares. Based on an average daily volume of 11,739,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 19.3% of the shares of the company are short sold.
Told the guys here 2 weeks ago that I won't sell my other half until we see $10.00 :)
C4 Therapeutics, or C4T, is a clinical-stage biopharmaceutical company focused on developing a new generation of medicines that harness targeted protein degradation (TPD). To achieve this objective, C4T utilizes its proprietary TORPEDO platform to design, analyze and predict degrader performance. Earlier this month, it signed a collaboration deal with Merck to discover and develop degrader-antibody conjugates (DACs) with an initial focus on one oncology target.
C4 Therapeutics currently carries a Zacks Rank #2. In the past 60 days, Loss estimates for 2024 have improved from $2.77 per share to $2.55. The company has an ABR of 1.91. Based on these analyst projections, we expect an average price target of $16.82, indicating a 277.13% upside to the current closing price of $5.27
This war is over when I say its over :)
This is where we fight!
Whoops. Wrong board
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |